| Identification | Back Directory | [Name]
Y06137 | [CAS]
2226534-49-0 | [Synonyms]
Y06137
Y-06137,Inhibitor,Y06137,inhibit,Y 06137,Epigenetic Reader Domain
1,2-Benzisoxazole, 5-[1-(cyclohexylmethyl)-6-[(3S)-3-methyl-4-morpholinyl]-1H-benzimidazol-2-yl]-3-methyl- | [Molecular Formula]
C27H32N4O2 | [MOL File]
2226534-49-0.mol | [Molecular Weight]
444.57 |
| Chemical Properties | Back Directory | [Boiling point ]
656.9±65.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 62.5 mg/mL (140.59 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
5.91±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Y06137 is a potent and selective BET inhibitor for treatment of castration-resistant prostate cancer (CRPC). Y06137 binds to the BRD4(1) bromodomain with a Kd of 81 nM[1]. | [in vivo]
Y06137 (50 mg/kg, i.p. injection, 5 times per week, 25 days) demonstrates therapeutic effects in a C4-2B CRPC xenograft tumor model in mice. Y06137 is well tolerated in the treated mice, based on the weight of the animal body and their general behavior[1]. | Animal Model: | Four-week-old male mice (strain: C.B-17/IcrHsd-Prkdcscid for C4-2B) with C4-2B mouse xenograft model[1] | | Dosage: | 50 mg/kg, 100 μL | | Administration: | Intraperitoneal (i.p.) injection, 5 times per week, 25 days | | Result: | Exhibited strong antitumor activities during the 25-day treatment period, with a tumor growth inhibition (TGI) of 51%. |
| [IC 50]
BRD4(1): 81 nM (Kd) | [References]
[1] Zhang M, et al. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). J Med Chem. 2018 Apr 12;61(7):3037-3058. DOI:10.1021/acs.jmedchem.8b00103 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|